Clinical Advisory Board

Elliott C. Dasenbrook, MD MHS

Dr. Dasenbrook is Assistant Professor of Medicine and Associate Director of the Adult Cystic Fibrosis Program at Case Western Reserve University (CWRU) School of Medicine. He is a leading researcher on the effects of MRSA in Cystic Fibrosis patients. Dr. Dasenbrook co-authored a ground breaking study in 2010 that showed the impact on survival is a life span that is a median 6.2 years shorter in CF patients with MRSA than those without.

Patrick Flume, MD

Dr. Flume is a Professor of Medicine and Pediatrics at the Medical University of South Carolina. He oversees a rapidly growing Cystic Fibrosis Center, including the largest adult CF program in South Carolina. He is recognized by the national and international CF community having served on the CF Foundation Center Committee, the Adult Care Consensus Committee, and the Advisory Task Force on Adult Issues, the Professional Education Committee, and as founding co-chair of the CF Foundation Pulmonary Practice Guidelines Committee.

Taneli Jouhikainen, MD, PhD, MBA

Dr. Jouhikainen is COO of Savara Pharmaceuticals.

Michael Konstan, MD

Dr. Konstan is the Chairman of the Department of Pediatrics of Case Western Reserve University (CWRU) School of Medicine. In addition, he is the director of The LeRoy W. Matthews Cystic Fibrosis Center at Rainbow Babies and Children’s Hospital. Dr. Konstan’s academic career has focused on developing new therapies for the lung disease of cystic fibrosis (CF), with a special interest in anti-inflammatory therapies and clinical trial design. He has led numerous national and international CF trials of potentially new therapies for Cystic Fibrosis, and is regarded as a national and international expert in this disease.

Felix Ratjen , MD, FRCP(C)

Dr. Ratjen is the Division Chief of Paediatric Respiratory Medicine at The Hospital for Sick Children, Professor of Paediatrics at The University of Toronto, and Senior Scientist at the Research Institute in the Department of Physiology and Experimental Medicine. He is co-leader of the Cystic Fibrosis centre at SickKids and Medical Director of the Clinical Research Unit. Dr. Ratjen has conducted multiple clinical trials addressing cystic fibrosis lung disease including new therapeutic strategies, treatment of airway infections, airway inflammation and other important aspects of the disease.

Grant Waterer, MBBS

Dr. Waterer is Head of Unit/Professor at the School of Medicine and Pharmacology Royal Perth Hospital Unit at the University of Western Australia. He is a respiratory specialist seeing general respiratory diseases but with a particular interest in pulmonary infectious diseases.